Fact.MR has announced the addition of the “Cannabidiol Market Forecast, Trend Analysis Competition Tracking – Global Review 2017 to 2026″report to their offering.
This press release was orginally distributed by SBWire
Rockville, MD — (SBWIRE) — 03/22/2019 — The cannabidiol marketplace is likely to witness significant RD investment in the pharmaceutical industry as a broad-spectrum pharmaceutical therapeutics. Multiple scientific studies have shown promising results of cannabidiol for its potential in the treatment of a number of diseases. Following which the cannabidiol market is marked by a considerable cannabidiol therapeutics getting FDA approval or moving ahead in the human clinical trials.
For instance, INSYS Therapeutics, Inc. announced in March 2018, the initiation of Phase III clinical trial of cannabidiol oral solution for the treatment of a rare type of pediatric epilepsy, infantile spasms. GW Pharmaceutical plc and Greenwich Biosciences, GW’s subsidiary announced FDA’s approval of EPIDIOLEX® cannabidiol
... read more at: http://www.digitaljournal.com/pr/4220568